Pulocimab is a new recombinant all-human monoclonal antibody drug against vascular endothelial growth factor receptor 2 (VEGFR-2) independently developed by AD Pharmaceuticals, with completely independent intellectual property rights and global development rights. It is a better generation of tumor angiogenesis inhibitor and is used to treat gastric cancer and various solid tumors. Pulocimab does not activate ADCC and can bind specifically to human VEGFR-2 protein with high affinity, which blocks the binding between VEGF and VEGFR-2, and effectively inhibits the proliferation of vascular endothelial cells induced by VEGF/VEGFR-2 binding, thus interfering with tumor angiogenesis and inhibiting the occurrence and development of tumors.

According to related research, VEGFR-2 monoclonal antibody has good anti-tumor effect in malignant tumors such as gastric cancer or adenocarcinoma of gastroesophageal junction, metastatic non-small cell lung cancer, hepatocellular carcinoma and colorectal cancer, and has good synergistic anti-tumor activity with PD-1 monoclonal antibody.

AD Pharmaceuticals is accelerating the studies of Pulocimab in the treatment of related tumors, and will actively explore the related studies on the combination therapies of Pulocimab and other drugs in the future.